Germany · Delayed Price · Currency is EUR Zelira Therapeutics Statistics
Total Valuation
FRA:G1G has a market cap or net worth of EUR 2.31 million. The enterprise value is 3.61 million.
| Market Cap | 2.31M |
| Enterprise Value | 3.61M |
Important Dates
The last earnings date was Wednesday, November 26, 2025.
| Earnings Date | Nov 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 11.90M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.20% |
| Shares Change (QoQ) | +2.40% |
| Owned by Insiders (%) | 40.23% |
| Owned by Institutions (%) | 7.94% |
| Float | 6.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6,319.93 |
| PB Ratio | -0.97 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.78 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.11
| Current Ratio | 0.11 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.61 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -83.30% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 100.72% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.93 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.82% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -50.82% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 0.22 |
| Relative Strength Index (RSI) | 48.75 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:G1G had revenue of EUR 366 and -2.03 million in losses. Loss per share was -0.18.
| Revenue | 366 |
| Gross Profit | -448,245 |
| Operating Income | -2.41M |
| Pretax Income | -2.15M |
| Net Income | -2.03M |
| EBITDA | -2.33M |
| EBIT | -2.41M |
| Loss Per Share | -0.18 |
Balance Sheet
The company has 3,161 in cash and 1.20 million in debt, giving a net cash position of -1.19 million.
| Cash & Cash Equivalents | 3,161 |
| Total Debt | 1.20M |
| Net Cash | -1.19M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -2.40M |
| Book Value Per Share | -0.21 |
| Working Capital | -2.78M |
Cash Flow
| Operating Cash Flow | -2.74M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -659,095.63% |
| Pretax Margin | -587,181.15% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:G1G does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.20% |
| Shareholder Yield | -1.20% |
| Earnings Yield | -87.56% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 14, 2022. It was a reverse split with a ratio of 0.0057142857.
| Last Split Date | Apr 14, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.0057142857 |
Scores
FRA:G1G has an Altman Z-Score of -106.28. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -106.28 |
| Piotroski F-Score | n/a |